Want to see INTS full AI Analyst Report?
Top Page
Intensity Therapeutics, Inc.
(NASDAQ:INTS)
Select Model
Select Model
Rating:48Neutral
Price Target:
$4.00
▼(-10.11% Downside)
Action:Reiterated
Date:08/11/26
The score is primarily constrained by weak fundamentals typical of an R&D-stage biotech (no revenue, ongoing losses, and persistent cash burn), despite low balance-sheet leverage. Technicals are neutral-to-slightly bearish, offering limited support. The earnings call adds some offset from tangible clinical/program progress and early efficacy signals, but substantial incremental funding needs and higher losses keep risk elevated, and valuation is challenged by negative earnings and no dividend support.
Positive Factors
Low financial leverage
The company’s very low debt load and positive equity materially reduce near-term solvency risk and interest burden. This structural balance-sheet strength provides operating flexibility while pursuing partnerships or capital raises, supporting continuity of clinical programs over the next 2–6 months.
Negative Factors
No revenue; persistent net losses
As an R&D-stage biotech with no product revenue, ongoing material operating losses are structural. Persistent negative profitability prevents self-funding of trials, erodes shareholder equity over time, and creates reliance on external capital that can alter strategic options or dilute long-term holders.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
The company’s very low debt load and positive equity materially reduce near-term solvency risk and interest burden. This structural balance-sheet strength provides operating flexibility while pursuing partnerships or capital raises, supporting continuity of clinical programs over the next 2–6 months.
Read all positive factors
Intensity Therapeutics, Inc. (INTS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.06M
Dividend YieldN/A
Average Volume (3M)51.49K
Price to Earnings (P/E)―
Beta (1Y)0.39
Revenue GrowthN/A
EPS Growth76.63%
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.83
Shares Outstanding3,264,879
10 Day Avg. Volume22,859
30 Day Avg. Volume51,488
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)11.72
Price to Sales (P/S)0.00
P/FCF Ratio-15.07
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.00Price Target Upside237.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.69
Revenue Forecast (FY)N/A
Intensity Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, ...
How the Company Makes Money
null...
Intensity Therapeutics, Inc. Earnings Call Summary
Earnings Call Date:Aug 11, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 17, 2026
Earnings Call Sentiment Neutral
The call communicated meaningful operational and scientific progress — resumption of two clinical programs, protocol amendments, encouraging early efficacy signals (notably a 71% vs 42% pCR in a small INVINCIBLE-4 cohort), and a high-impact peer-reviewed publication — alongside active business development engagement. However, substantial funding needs (estimated ~$30M to complete the Phase III), a widening quarterly net loss (+19%), prior enrollment/statistical uncertainties, and recent safety-driven pauses temper the outlook. Progress is tangible but contingent on additional capital or partnerships to fully realize the programs.Positive Updates
Improved cash position and recent capital raises
Cash and cash equivalents of $9.5M as of June 30, 2026; raised $1.6M net proceeds in Q2 2026 via a $60M ATM facility and an additional $1.3M after quarter-end; company has raised over $23M since Q2 2025 to strengthen the balance sheet.
Negative Updates
Insufficient capital to fully complete Phase III
Management estimates an incremental ~$30M is required to complete the INVINCIBLE-3 study; current cash (~$9.5M) and opportunistic ATM use are not sufficient to open all planned sites or fully fund the program without additional capital raises or partnerships.
Read all updates
Q2-2026 Updates
Positive
Negative
Improved cash position and recent capital raises
Cash and cash equivalents of $9.5M as of June 30, 2026; raised $1.6M net proceeds in Q2 2026 via a $60M ATM facility and an additional $1.3M after quarter-end; company has raised over $23M since Q2 2025 to strengthen the balance sheet.
Read all positive updates
Company Guidance
The company said it exited June 30, 2026 with $9.5M in cash, raised $1.6M net from its $60M ATM in Q2 and an additional $1.3M since quarter-end (and has raised over $23M since Q2 2025), burned $4.2M from operations in H1 2026 and expects operating cash burn to average about $1.0M per month in H2 2026, and reported Q2 R&D expense of $1.8M (up 19% YoY), clinical trial expense of $1.2M, G&A of $1.3M (up 7% YoY) and a Q2 net loss of $3.0M (up $470k, or 19%); management said it will continue to use the ATM opportunistically but needs roughly $30M of incremental capital to fully complete the Phase III INVINCIBLE‑3 program, will resume limited U.S. enrollment in the coming months while assessing broader site activations as funding is raised, and expects to enroll roughly 45 more patients in INVINCIBLE‑4 to target completion by end of 2027 (early randomized data: 14 patients showed 71% pCR vs 42% SOC; median tumor size ~2.4 cm).Intensity Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -7.00K | -26.00K | 0.00 | -147.00K | 0.00 | 0.00 |
| EBITDA | -8.50M | -11.61M | -16.27M | -10.09M | -7.32M | -7.88M |
| Net Income | -11.16M | -11.61M | -16.27M | -10.54M | -7.58M | -7.90M |
Balance Sheet | ||||||
| Total Assets | 11.52M | 14.10M | 4.78M | 17.30M | 1.76M | 5.22M |
| Cash, Cash Equivalents and Short-Term Investments | 9.53M | 11.92M | 2.59M | 14.78M | 1.31M | 4.54M |
| Total Debt | 95.00K | 110.00K | 138.00K | 158.00K | 4.49M | 2.34M |
| Total Liabilities | 2.31M | 2.23M | 1.86M | 4.13M | 16.86M | 13.90M |
| Stockholders Equity | 9.21M | 11.88M | 2.92M | 13.16M | -15.10M | -8.68M |
Cash Flow | ||||||
| Free Cash Flow | -8.95M | -9.23M | -15.22M | -7.21M | -5.48M | -6.83M |
| Operating Cash Flow | -8.95M | -9.23M | -15.22M | -7.21M | -5.48M | -6.83M |
| Investing Cash Flow | 0.00 | 0.00 | 6.35M | -6.02M | 0.00 | 0.00 |
| Financing Cash Flow | 16.27M | 18.56M | 2.90M | 20.47M | 2.25M | 2.05M |
Intensity Therapeutics, Inc. Technical Analysis
Negative
4.45
Price Trends
4.24
Negative
4.72
Negative
7.27
Negative
Market Momentum
-0.09
Positive
37.96
Neutral
26.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INTS, the sentiment is Negative. The current price of 4.45 is above the 20-day moving average (MA) of 4.32, above the 50-day MA of 4.24, and below the 200-day MA of 7.27, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 37.96 is Neutral, neither overbought nor oversold. The STOCH value of 26.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INTS.
Intensity Therapeutics, Inc. Risk Analysis
Intensity Therapeutics, Inc. disclosed 62 risk factors in its most recent earnings report. Intensity Therapeutics, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Intensity Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $19.82M | -0.57 | -264.79% | ― | ― | 77.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $13.06M | -0.82 | -136.82% | ― | ― | 76.63% | |
47 Neutral | $13.04M | -0.36 | -346.03% | ― | ― | 30.16% | |
44 Neutral | $11.96M | -0.25 | -503.79% | ― | ― | 82.28% | |
42 Neutral | $20.13M | -0.19 | 411.46% | ― | -51.03% | -35.20% | |
40 Underperform | $13.19M | -0.07 | -901.32% | ― | ― | 75.09% |
* Healthcare Sector Average
INTS
Intensity Therapeutics, Inc.
3.96
-3.41
-46.25%
CLRB
Cellectar Biosciences
2.60
-1.74
-40.09%
PDSB
PDS Biotechnology
0.23
-0.96
-80.67%
GTBP
GT Biopharma
0.30
-1.04
-77.91%
CELU
Celularity
0.70
-2.79
-80.03%
SNTI
Senti Biosciences
0.45
-1.07
-70.46%
Intensity Therapeutics, Inc. Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Intensity Therapeutics Stockholders Approve Proposals at Annual Meeting
Positive
Jun 16, 2026
On June 16, 2026, Intensity Therapeutics, Inc. held its annual meeting of stockholders via live webcast, with about 40.74% of eligible common shares represented, constituting a quorum. Stockholders elected two Class III directors, Dr. Emer Leahy a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.